en en en id ca en en en en en en en en en en en en en en en en en en en en en fr en de en en en en en en en en en en en en en en ceb en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en fr fr en en en en en en en en en en en en en jbo en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en fa en en en en en en en en en en en en en en en en en en en en en en en en
Caris Life Sciences to Present Key Research Findings on its Molecular Intelligence Platform at the 2017 ASCO Annual Meeting | Caris Life Sciences
Presentations Demonstrate Utility of Tumor Profiling to Guide Individualized Treatment
IRVING, Tex., May 24, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of 11 abstracts, including an oral abstract session, two poster discussion sessions and eight poster sessions, by the American Society of Clinical Oncology (ASCO) for presentation at its annual meeting, being held June 2-5, 2017 in Chicago. The studies were conducted in collaboration with industry-leading academic and clinical institutions employing the company’s proprietary Caris Molecular Intelligence® Comprehensive Genomic Profiling Plus (CGP+) tumor profiling platform. Caris Molecular Intelligence identifies molecular aberrations which aid clinicians in delivering the most optimal and personalized treatment plan for each patient.
David Spetzler, MS, PhD, MBA, President and Chief Scientific Officer of Caris, commented, “Our Comprehensive Genomic Profiling Plus approach to tumor profiling provides a unique opportunity to decode cancer and guide more precise and personalized treatment decisions. Our platform helps both clinicians and biopharmaceutical companies better understand cancer biology and ultimately increase the chances for successful outcomes for each cancer patient. We are excited to be presenting a multitude of supporting data during this year’s ASCO.”
Monday, June 5, 8:24 – 8:36 a.m. CT, S404
Oral Abstract Session: Tumor Biology “Prevalence of homologous recombination deficiency among all tumor types” presented by Arielle Lutterman Heeke, MD, MedStar Georgetown Lombardi, Abstract 1502.
Saturday, June 3, 4:45 – 6:00 p.m. CT, S406
Poster Discussion Session: Tumor Biology “Characterization of tumor mutation load (TML) in solid tumors” presented by Mohamed Salem, MD, MedStar Georgetown Lombardi, University of Southern California, Karmanos Cancer Institute, Levine Cancer Institute, Fox Chase Cancer Center, Abstract 11517, Poster 217.
Monday, June 5, 4:45 – 6:00 p.m. CT, S404
Poster Discussion Session: Brain Cancer “RNASeq analysis of glioma tumors reveal targetable gene fusions” presented by Deepa S. Subramaniam, MD, MedStar Georgetown Lombardi, Barrow Neurological Institute, MD Anderson Cancer Center, Abstract 2019, Poster 261.
Saturday, June 3, 8:00 – 11:30 a.m. CT, Hall A
Poster Session: Tumor Biology “Impact of primary tumor location on genetic alterations” presented by Mohamed E. Salem, MD, MedStar Georgetown Lombardi, University of Southern California, Karmanos Cancer Institute, Levine Cancer Institute, Abstract 3578, Poster 201.
Saturday, June 3, 8:00 – 11:30 a.m. CT, Hall A
Poster session: Gastrointestinal (Colorectal) Cancer “Impact of patient age on molecular alterations in left-sided colorectal tumors” presented by Benjamin A. Weinberg, MD, MedStar Georgetown Lombardi, Abstract 3592, Poster 215.
Saturday, June 3, 1:15 – 4:45 p.m. CT, Hall A
Poster session: Breast Cancer “Molecular profiling comparison of breast cancer subtypes in young women and older women” presented by Antionette R. Tan, MD, Levine Cancer Institute, Abstract 11581, Poster 281.
Saturday, June 3, 1:15 – 4:45 p.m. CT, Hall A
Poster session: Gastrointestinal (Colorectal) and Uterine Cancers “Variable DNA mismatch repair associated gene profiles in colorectal versus uterine cancers” presented by Tabari Baker, PhD, Fox Chase Cancer Center, Ohio State University, Abstract 11610, Poster 310.
Sunday, June 4, 8:00 – 11:30 a.m. CT, Hall A
Poster session: Breast Cancer “Distribution of receptor tyrosine kinase (RTK) nsSNPs in breast cancer (BC) patients (pts) using Next-Generation Sequencing (NGS)” presented by Lindsay Morris, MD, West Cancer Center, Abstract 1080, Poster 72.
Sunday, June 4, 8:00 – 11:30 a.m. CT, Hall A
Poster session: Tumor Biology “Potential therapeutic genomic alterations in desmoplastic small round blue cell tumor” presented by Joanne Xiu, PhD, Kymera Independent Physicians, All Saints University, Abstract 11066, Poster 389.
Sunday, June 4, 8:00 – 11:30 a.m. CT, Hall A
Poster session: Genitourinary Cancer “Spectrum of tumor mutational load (TML) in genitourinary (GU) cancers” presented by Muhammed Azam Hussain, MD, Penn State University, Karmanos Cancer Institute, Abstract 4535, Poster 213.
Monday, June 5, 1:15 – 4:45 p.m. CT, Hall A
Poster session: Tumor Biology “Localization of non-receptor tyrosine kinase (nRTK) variants identified in solid tumor patients with Next-Generation Sequencing (NGS)” presented by Srishti Sareen, MD, West Cancer Center, Abstract 1536, Poster 194.
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company’s Comprehensive Genomic Profiling Plus (CGP+) molecular testing service and the world’s leading immunotherapy diagnostic expert, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal the molecular drivers of cancer and enable the delivery of personalized medicine. The ADAPT Biotargeting System™, the company’s revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.
Kirsten Thomas / Joanna Zimmerman
Tel: +1-508-280-6592 / +1-646-536-7006
Source: Caris Life Sciences
Caris Life Sciences Media Relations & Corporate Affairs
Caris Molecular Tumor Board
Laboratory Accreditations & Licenses
Privacy & Website Policies
Annual Notice to Physicians
© 2022 Caris Life Sciences. All rights reserved.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept,” you consent to the use of all cookies.
Do not sell my personal information.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.